07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Semprana dihydroergotamine regulatory update

Allergan said FDA issued the third complete response letter for a resubmitted NDA for Semprana dihydroergotamine for the acute treatment of migraines in adults. The company said the 2 specific items listed in the letter...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Tonix management update

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), New York, N.Y.   Business: Musculoskeletal, Neurology   Hired: Donald Kellerman as SVP of clinical development and regulatory affairs, formerly SVP of clinical development and medical affairs at Map Pharmaceuticals...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Company News

Principia Biopharma management update

Principia Biopharma Inc. , South San Francisco, Calif.   Business: Cancer, Autoimmune   Hired: Christopher Chai as CFO, formerly SVP and CFO of Map Pharmaceuticals Inc., which Allergan Inc. acquired; and Steven Gourlay as CMO,...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Civitas board of directors update

Civitas Therapeutics Inc. , Chelsea, Mass.   Business: Drug delivery, Neurology, Pulmonary   Appointed: Timothy Nelson as chairman, formerly CEO of Map Pharmaceuticals Inc. , which Allergan Inc. acquired  ...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Company News

MyoKardia management update

MyoKardia Inc. , San Francisco, Calif.   Business: Cardiovascular   Hired: Tassos Gianakakos as CEO, formerly SVP and CBO of Map Pharmaceuticals Inc. , which Allergan Inc. acquired; he succeeds Charles Homcy, who remains a...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Company News

Mimetica, Telesso Technologies Ltd. deal

Telesso will acquire Mimetica in a stock deal that values Mimetica at A$16 million ($14 million). Telesso will issue 63 million shares to Mimetica shareholders at A$0.25 per share, plus 3 million options at A$0.11...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

Levadex dihydroergotamine regulatory update

EMA's CHMP recommended restricting the use of medicines containing ergot derivatives, including dihydroergotamine, from treating several conditions involving blood circulation problems, problems with memory and sensation or to prevent migraines because the risks are greater...
07:00 , Apr 22, 2013 |  BC Week In Review  |  Clinical News

Levadex dihydroergotamine regulatory update

Allergan said FDA issued a complete response letter for a resubmitted NDA for Levadex dihydroergotamine for the acute treatment of migraines in adults. The company said it has already addressed the main issues raised by...
00:11 , Apr 17, 2013 |  BC Extra  |  Company News

Second complete response for Levadex

Allergan Inc. (NYSE:AGN) said FDA issued a complete response letter for a resubmitted NDA for Levadex dihydroergotamine for the acute treatment of migraines in adults. The company said it has already addressed the main issues...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

Map Pharmaceuticals, Allergan deal

Allergan completed its acquisition of Map for $25 per share in cash. Allergan paid Map a total value of about $961 million, plus transaction fees and expenses. Map is now a wholly-owned subsidiary of Allergan...